By contrast, NPM1 wild-type AML with FLT3-ITD AR >0.5 (FLT3-ITDhigh) are classified as “adverse-risk,” while AML NPM1-mutated/FLT3-ITDhigh are considered “intermediate-risk” (6) (Figure 1). This evidence concerns the gene NPM1 and acute myeloid leukemia.